Micromedic Technologies Ltd. (TASE:MCTC) subsidiary Biomark Ltd. has obtained a patent for its cancer biomarker technology from the European Patent Office. The patent was issued for "Methods and kits for early detection of cancer or predisposition thereto". Final approval of the patent is subject to a hearing of objections, if any are filed.
The patent applies to Biomark's use of the CD24 Oncogene for colorectal adenoma, the precursor of colorectal cancer, by testing blood, saliva, feces, or urine samples.
The patent is registered in the name of a research fund of the Tel Aviv Medical Center Ltd. from which Biomark licenses CD24.
Micromedic's share price fell 0.7% by mid-afternoon to NIS 3.74, giving a market cap of NIS 58 million.
Published by Globes [online], Israel business news - www.globes-online.com - on August 12, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010